391 related articles for article (PubMed ID: 22675660)
1. Antiangiogenic therapy for ischemic retinopathies.
Al-Latayfeh M; Silva PS; Sun JK; Aiello LP
Cold Spring Harb Perspect Med; 2012 Jun; 2(6):a006411. PubMed ID: 22675660
[TBL] [Abstract][Full Text] [Related]
2. Does laser still have a role in the management of retinal vascular and neovascular diseases?
Shah AM; Bressler NM; Jampol LM
Am J Ophthalmol; 2011 Sep; 152(3):332-339.e1. PubMed ID: 21742309
[TBL] [Abstract][Full Text] [Related]
3. Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept.
Liu H; Ma Y; Xu HC; Huang LY; Zhai LY; Zhang XR
Curr Eye Res; 2020 Dec; 45(12):1467-1476. PubMed ID: 32631094
[No Abstract] [Full Text] [Related]
4. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
Andreoli CM; Miller JW
Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
Emerson MV; Lauer AK
BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122
[TBL] [Abstract][Full Text] [Related]
6. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.
Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A
Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744
[TBL] [Abstract][Full Text] [Related]
7. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
[TBL] [Abstract][Full Text] [Related]
8. [Intraocular antiangiogenic drugs in clinical application advantages and disadvantages].
Li XX
Zhonghua Yan Ke Za Zhi; 2012 Oct; 48(10):870-3. PubMed ID: 23302238
[TBL] [Abstract][Full Text] [Related]
9. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
[TBL] [Abstract][Full Text] [Related]
10. [Role of VEGF in diseases of the retina].
Barquet LA
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():3-5. PubMed ID: 25925044
[TBL] [Abstract][Full Text] [Related]
11. [Aging and retinal vascular diseases].
Takagi H
Nippon Ganka Gakkai Zasshi; 2007 Mar; 111(3):207-30; discussion 231. PubMed ID: 17402563
[TBL] [Abstract][Full Text] [Related]
12. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
Eyetech Study Group
Retina; 2002 Apr; 22(2):143-52. PubMed ID: 11927845
[TBL] [Abstract][Full Text] [Related]
13. [Results of trabeculectomy with anti-VGEF therapy in the treatment of neovascular glaucoma secondary to retinal vein occlusion (report of 21 cases followed at Bukavu Eye Clinic from January 1 to December 31th, 2015)].
Kabesha TB; Kabesha D; Maloba V; Mwamba C; Chenge B; Mukalay A
J Fr Ophtalmol; 2017 Jan; 40(1):17-21. PubMed ID: 27884546
[TBL] [Abstract][Full Text] [Related]
14. [Management of aflibercept in routine clinical practice].
Cabrera López F
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():29-34. PubMed ID: 25925049
[TBL] [Abstract][Full Text] [Related]
15. A Review: Proteomics in Retinal Artery Occlusion, Retinal Vein Occlusion, Diabetic Retinopathy and Acquired Macular Disorders.
Cehofski LJ; Honoré B; Vorum H
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28452939
[TBL] [Abstract][Full Text] [Related]
16. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
Tolentino M
Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
[TBL] [Abstract][Full Text] [Related]
17. [New drug VEGF Trap-Eye--Eylea--and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia].
Rejdak R; Szkaradek M; Taslaq W; Kałuzny JJ; Grieb P; Jünemann AG
Klin Oczna; 2012; 114(4):308-10. PubMed ID: 23461161
[TBL] [Abstract][Full Text] [Related]
18. Applications of nanomaterials in anti-VEGF treatment for ophthalmic diseases.
Teng L; Sun Y; Teng S; Hui P
J Biomed Mater Res A; 2024 Feb; 112(2):296-306. PubMed ID: 37850566
[TBL] [Abstract][Full Text] [Related]
19. [What can anti-VEGF therapy achieve in clinical routine? : Effectiveness of anti-VEGF therapy in patients with macular diseases in clinical routine on 1492 eyes in Austria].
Wiesinger K; Reinelt P; Ennemoser A; Edelmayr M; Schönherr U
Ophthalmologe; 2017 Jul; 114(7):639-645. PubMed ID: 27815675
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage.
Silva RLE; Kanan Y; Mirando AC; Kim J; Shmueli RB; Lorenc VE; Fortmann SD; Sciamanna J; Pandey NB; Green JJ; Popel AS; Campochiaro PA
Sci Transl Med; 2017 Jan; 9(373):. PubMed ID: 28100839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
